The PTEN tumor suppressor is the body’s prime defense against cancer. However, it becomes deactivated or eliminated during cancer progression. Loss of PTEN reduces response to over 30 FDA-approved drugs, including immuno-oncology antibodies. Moreover, as PTEN cannot penetrate cancer cells, it is practically “undruggable”.
TheraPten has engineered cpPTEN, a cell-penetrating form of the PTEN tumor suppressor that is able to enter cancer cells and kill them. cpPTEN is delivered via a lipid nanoparticle (LNP) formulation for intravenous injection that is manufactured by a strong industrial partner.
Hence, LNP-cpPTEN is expected to have profound impact in cancer care.